Romanos tapped as Crescendo CEO

> Crescendo Biologics has named Mike Romanos CEO. Romanos has been Chief Scientific Officer of the company since May 2009 and has led the formation of the company and the development of its proprietary antibody fragment technologies. Crescendo release

> Karyopharm Therapeutics has hired Michael Kauffman as its CEO. Karyopharm release

> TranS1 names Ken Reali as CEO. Story 

> Regulus Therapeutics has promoted Garry Menzel to COO and executive VP of Finance. Regulus release

> CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, has named Sean McCarthy as chief business officer. CytomX release

> Novo Nordisk has appointed Anne Phillips as VP, Clinical Development, Medical and Regulatory Affairs for North America. Novo Nordisk release

> Constellation Pharmaceuticals has named James Audia as CSO. Audia joins Constellation following a highly productive career in drug discovery at Eli Lilly. Constellation release

> Cempra Pharmaceuticals has announced that Carl Foster has been named executive VP of Business Development. Cempra release

> ZIOPHARM Oncology has appointed Mark Thornton executive VP and chief development officer. ZIOPHARM release

> Momenta Pharmaceuticals has announced that Young Kwon has been named VP of Business Development. Momenta release

> Semprus BioSciences has appointed Ulla Wallin as the company's first director of clinical affairs. Semprus release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.